Redx to Present Poster at ASN Kidney Week

RNS Number : 2566E

Redx Pharma plc

27 October 2022

 

REDX PHARMA PLC

("Redx" or "the Company")

Redx to Present Poster on Preclinical Efficacy of a Novel, Selective Discoidin Domain Receptor 1 Inhibitor at the American Society of Nephrology Kidney Week

Alderley Park, UK, 27 October 2022 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces it will present a poster on its novel preclinical Discoidin Domain Receptor 1 (DDR1) inhibitor programme at the American Society of Nephrology (ASN) Kidney Week (3-6 November 2022, Orlando, Florida).

As announced in January 2022, Redx is developing potent proprietary DDR inhibitors with drug-like characteristics that are now in lead optimisation . The poster will present compelling preclinical data on REDX12271, a novel, potent, selective and orally active DDR1 inhibitor, in chronic kidney disease models. DDRs are receptor tyrosine kinases containing a discoidin homology domain in their extracellular region and which act as non-integrin collagen receptors. There are two DDR receptors, DDR1 and DDR2, and DDR expression is increased in many fibrotic diseases. DDRs have recently gained traction as new druggable targets with the potential to treat multiple fibrotic conditions, including kidney fibrosis. The poster supports the further investigation of selective inhibition of DDR1 as a potential novel approach for the treatment of renal fibrosis associated with chronic kidney disease.

Title:	REDX12271 is a novel, selective DDR1 inhibitor with the potential to treat multiple chronic kidney diseases
Poster Board:	TH-PO433
Day/Date:	Thursday, 3 November 2022
Time:	10:00-12:00
Session name and category:	Posters Glomerular Diseases: Inflammation and Fibrosis [PO1301]

A copy of the poster will be made available  on the Company's website following the presentation at:  https://www.redxpharma.com/scientific-publications/  

About Chronic Kidney Disease

Defined as a persistent abnormality in kidney structure or function (e.g. glomerular filtration rate [GFR] <60 mL/min/1.73 m2 or albuminuria ≥30 mg per 24 hours) for more than 3 months, chronic kidney disease (CKD) affects 8% to 16% of the population worldwide. CKD is most commonly attributed to diabetes and hypertension. However, less than 5% of patients with early CKD report awareness of their disease. Among individuals diagnosed as having CKD, staging and new risk assessment tools that incorporate GFR and albuminuria can help guide treatment, monitoring, and referral strategies. While CKD is progressive, optimal management can slow its progression to end-stage renal disease (ESRD). This includes cardiovascular risk reduction (e.g., statins and blood pressure management), treatment of albuminuria (e.g. angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and more recently SGLT2 inhibitors), avoidance of potential nephrotoxins (e.g. nonsteroidal anti-inflammatory drugs). Renal fibrosis, characterized by tubulointerstitial fibrosis and glomerulosclerosis, is one the final manifestations of CKD as it progresses and is associated with high morbidity. There are currently no approved treatments to address the interstitial fibrotic component of this disease.¹

For further information, please contact:
Redx Pharma Plc UK Headquarters Caitlin Pearson, Head of Communications  [e-mail] Lisa Anson, Chief Executive Officer		T: [phone]
US Office Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser)		T: [phone]
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker)		T: [phone]
Claes SpŒng/ Satheesh Nadarajah/ David Wilson
Panmure Gordon (UK) Limited (Joint Broker)		T: [phone]
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting		T: [phone]
Simon Conway/ Ciara Martin

About Redx Pharma Plc  

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is currently in pre-IND stage, with Phase 1 clinical studies expected to commence in 2023. 

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a preclinical pan-RAF inhibitor which has received IND clearance from the US FDA, and an early stage oncology research collaboration. 

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/  

¹ Taken in part from Chen TK et al;  JAMA. 2019 Oct 1; 322(13): 1294Ð1304.

 

END

 

 

NRADGBDGUUDDGDL